In this study, we investigated whether sorafenib could show an enhanced anticancer effect against CRC cells following calcium-mediated inhibition of the bypassable survival signaling pathways of Src/FAK/Akt/mTOR. This evidence concerns the gene PTK2 and colorectal carcinoma.